IL-31: State of the Art for an Inflammation-Oriented Interleukin

Interleukin 31 belongs to the IL-6 superfamily, and it is an itch mediator already studied in several diseases, comprising atopic dermatitis, allergic pathologies, and onco-hematological conditions. This research aims to assess the role of this cytokine in the pathogenesis of these conditions and its potential therapeutic role. The research has been conducted on articles, excluding reviews and meta-analysis, both on animals and humans. The results showed that IL-31 plays a crucial role in the pathogenesis of systemic skin manifestations, prognosis, and itch severity. Traditional therapies target this interleukin indirectly, but monoclonal antibodies (Mab) directed against it have shown efficacy and safety profiles comparable with biological drugs that are already available. Future perspectives could include the development of new antibodies against IL-31 both for humans and animals, thus adding a new approach to the therapy, which often has proven to be prolonged and specific for each patient.

Automated summary

This research examines the role of interleukin 31 in various diseases, including skin conditions, allergic pathologies, and hematological disorders. It demonstrates that interleukin 31 is crucial in the pathogenesis, prognosis, and itch severity of these conditions. Monoclonal antibodies targeting interleukin 31 have shown promising efficacy and safety, offering a new approach to therapy.